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Abstract From the latex of Jatropha curcas L. (Euphorbiaceae) 
a novel cyclic octapeptide was isolated, which we named curcacy- 
cline A. The compound was found to contain one threonine, one 
valine, two glycine, and four leucine residues. By two-dimensional 
~H-NMR spectroscopy (HOHAHA and ROESY), its sequence 
was determined to be GiyLLeu2-Leu3-Gly4-ThrS-Val6-LeuT-Leu s- 
Gly% Curcacycline A displays a moderate inhibition of (i) classi- 
cal pathway activity of human complement and (ii) proliferation 
of human T-cells. 
and two-dimensional 1H-NMR spectroscopy (HOHAHA and 
ROESY). 
2. Experimental 
2.1. Plant material 
Jatropha curcas L. plants grown as hedges in Jepara (near Kudus, 
Java, Indonesia) were identified. Crude latex was obtained by cutting 
off leaf stalks, adding a few drops of EtOH to prevent he latex from 
excessive foaming. The latex was stored at -20°C until use. 
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1. Introduction 
Application of Jatropha species (Euphorbiaceae) in tradi- 
tional medicine has been frequently reported, e.g. Jatropha 
curcas is used in Nepal to treat malarial fever [1], and in Egypt 
to treat arthritis, gout and jaundice [2]. In Indonesia, the latex 
of J. multifida is externally applied to (infected) wounds and 
ulcers [3]. A l though seed oils of J. multifida, J. podagrica, 
J. curcas, and J. gossypifolia re known to possess toxic, skin 
irr itant and tumour-promot ing properties due to the presence 
of phorbol  esters [4,5], several compounds with ant i - tumour 
activities have also been found in Jatropha species. For  in- 
stance, from the roots of J .  gossypifolia, ja t rophone (a macrocy- 
clic diterpenoid) and 2~- and 2fl-hydroxyjatrophone w re iso- 
lated [6,7], and from J. macrorrhiza acetylaleuritolic acid (a 
triterpenoid) and ja t ropham (a lactam), which all displayed 
anti leukemic activity [8,9]. 
In our laboratory two immunomodulatory  c clic peptides 
were isolated from the latex of J. muhifida which both selec- 
tively inhibit classical pathway activity of human complement 
[3]. This led us to investigate other Euphorbiaceous plants for 
the presence of (biologically active) peptides. As a result, a 
novel cyclic peptide was isolated from the latex of Jatropha 
curcas, which we named curcacycline A. Curcacycline A also 
inhibits classical pathway complement activity, although in a 
lesser degree than the J. multifida cyclic peptides mentioned 
above. In addition, curcacycline A shows a moderate dose- 
dependent inhibit ion of human T-cell proliferation; direct cyto- 
toxic effects could not be observed. This paper describes the 
determination of the pr imary structure of curcacycline A by a 
combinat ion of amino acid analysis, FAB mass spectrometry, 
*Corresponding author. 
2.2. Isolation procedure 
To 50 ml of crude latex 200 ml of demineralized H20 and 2 ml of 
EtOH were added, after which the mixture was extracted with 3 x 500 
ml of EtOAc. EtOAc was removed from the extract under reduced 
pressure. The residue was dissolved in 1 ml of MeOH and fractionated 
on Sephadex LH-20 (Pharmacia; column dimensions: 1.4 cm i.d. x 40 
cm) with MeOH as eluting solvent at a flow rate of 0.35 ml/min; 
fractions of 8 ml were collected. Peptide-containing fractions were 
traced by TLC on precoated TLC plates 60 F254 (Merck) using a 
solvent system consisting of CHC13/MeOH/H20 = 5:4:1 in a saturated 
chamber. Peptides were detected with ClJo-tolidine reagent [10]. The 
peptide-containing fractions were combined, and further fractionated 
by preparative column chromatography on silica gel H (Merck, No. 
7736) using a Miniprep LC apparatus (Jobin Yvon, France; column 
dimensions: 1.4 cm i.d. x 40 cm; column pressure 8 bar) with CHC1J 
MeOH = 7 : 2 as eluting solvent (solvent pressure 2 bar); fractions of 16 
ml were collected. Fractions containing single peptides were combined; 
the solvent was evaporated under N 2. The residue was taken up in a few 
drops of MeOH and dissolved in H20. Subsequently, the aqueous 
solution was lyophilized yielding 26 mg of curcacycline A. 
2.3. Amino acid analysis 
Curcacycline A (0.5 mg, accurately weighed) was hydrolysed in l ml 
of 6 N HC1 in a sealed vial at 110°C for 24 h. HC1 was removed under 
reduced pressure, and the residue dissolved in 0.2 M Li-citrate buffer 
(pH 2.2). Amino acids were determined by cation-exchange chromatog- 
raphy on an LKB 4151 Alpha plus Amino Acid Analyser (Li-system) 
with ninhydrin detection. 
2.4. Mass spectrometry 
A positive ion spectrum was obtained by fast atom bombardment 
(FAB) using a JEOL SXI02 mass spectrometer. Glycerol was used as 
the matrix. The FAB mass spectrum of curcacycline A showed an 
[M+H] ÷ at m/z 767, and immonium ions at m/z 30, 72, 74, and 86. 
2.5. 1H-NMR spectroscopy 
Prior to IH-NMR spectroscopy, curcacycline A was dissolved in 
DMSO-d 6 (2 mg/ml). All experiments were performed at 300K. 
Two-dimensional tH-NMR experiments were carried out at 500 
MHz with a Bruker AMX-500 (Dept. of NMR spectroscopy, Bijvoet 
Center, Universiteit Utrecht). The processing of the spectra was per- 
formed on a Silicon Graphics workstation using the 'TRITON' soft- 
ware package (R. Boelens and R. Kaptein, Dept. of NMR Spectros- 
copy, Bijvoet Center, Universiteit Utrecht). 
A 2D HOHAHA spectrum was recorded using a 53 ms MLEV-17 
pulse sequence [11] with a field strength of 9,600 Hz. The time propor- 
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tional phase increment (TPPI) method [12,13] was used for t~ amplitude 
modulation, and 512 free induction decays (FIDs) of 1,024 complex 
data points each were collected. The spectral width was 5,000 Hz in 
both dimensions. The tl period was incremented from 3/is to 54.2 ms. 
The time domain data in both dimensions were weighted with a sine-bell 
function shifted by 1r/3 radians. The data were processed to give a phase 
sensitive spectrum of 1,024 × 1,024 real data points. 
A 2D ROESY spectrum was recorded using a simple 150 ms CW 
spin-lock pulse [14,15] with a field strength of 2,500 Hz. The carrier 
frequency was positioned at 4.64 ppm. Amplitude modulation i  t~ was 
accomplished with TPPI, and 640 FIDs of 1,024 complex data points 
each were recorded. The spectral width in both dimensions was 5,434 
Hz. The h period was incremented from 3/.ts to 61.9 ms. The time 
domain data in both dimensions were weighted with a sine-bell function 
shifted by Jr/3 radians. The data were processed to give a phase sensitive 
spectrum of 1,024 × 2,048 real data points. 
In addition to the 2D experiments described above, ~H-NMR spectra 
were recorded at 400 MHz on a Bruker MSL-400 (NMR Department, 
Gorlaeus Laboratories, State University Leiden); for the exchange of 
amide and OH (threonine) protons D20 was added. 
~H-Chemical shifts of amino acid residues expressed in ppm are listed 
in Table 1. 
3. Resu l ts  and d iscuss ion 
3.1. Amino acid analysis and mass spectrometry 
A compound was isolated from the latex of Jatropha curcas, 
which we named curcacycline A. The compound showed a 
C12/o-tolidine positive reaction which is indicative of (an) amide 
group(s) [10]. Amino acid analysis showed curcacycline A to 
contain (molar ratio in parenthesis) Gly (glycine; 39.2), Val 
(valine; 22.5), Thr (threonine; 22.1), and Leu (leucine; 77.9). 
Immonium ions (R-CH = NH~) in the FAB mass spectrum 
indicated the presence of Gly (m/z 30), Val (m/z 72), Thr (m/z 
74) and Leu/Ile(isoleucine) (m/z 86). These results indicate cur- 
cacycline A to be an octapeptide consisting of 2 Gly, 1 Val, 1 
Thr and 4 Leu for which in case of a linear structure amolecular 
mass of 784 can be calculated. FAB mass spectrometry, how- 
ever, revealed a molecular mass of 766 ([M+H] ÷ at m/z 767), 
indicating an extra loss (18) of one H20. Together with the 
observation that sequence fragments were absent in the FAB 
spectrum, this indicates a cyclic structure. It was concluded that 
curcacycline A is a cyclic octapeptide containing 2 Gly, 1 Val, 
1 Thr and 4 Leu residues. 
3.2. NMR spectroscopy 
The ~H-NMR spectrum of curcacycline A showed three clus- 
Table 1 
~H-Chemical shifts expressed 
(500 MHz) 
in ppm for curcacycline A in DMSO-d6 
Residue NH c~H flH others 
Gly I 8.59 3.92 ~ 
3.44 b 
Leu 2 7.54 4.62 1.42 ~ 
1.34 ~ 
Leu 3 8.52 3.92" 1.55 ~ 
1.38 ~ 
Gly 4 8.69 3.92 a 
3.44 b 
Thr 5 7.42 4.77 4.32 °
Val 6 7.75 4.10 2.34 
Leu 7 8.19 4.32" 1.63 ~ 
1.26 ¢ 
Leu s 8.04 3.92 ~ 1.43 ¢ 
5CH 3 0.83 d 
5CH3 0.89 °, 0.85 a 
yCH3 0.91 
OH 5.36 
yCH3 0.89 d, 0.85 a 
yCH 1.5Y 
8CH3 0.86 °, 0.78 d 
8CH3 0.87 d, 0.80 a 
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Fig. 1. Regions of the ROESY spectrum of curcacycline A (in DMSO- 
d6) showing inter-residue connectivities between s-protons (F~: 4.8-3.4 
ppm) and amide protons (F2:8.7-7.4 ppm). Intra- residue cross peaks, 
which also appeared in the HOHAHA spectrum, are boxed; unboxed 
signals represent sequential d~N(i, + 1) connectivities with the exception 
of cross peaks between ThrLNH (7.42 ppm) and ThrS-flH (4.32 ppm), 
ThrS-OH (5.36 ppm) and ThrS-NH, ThrS-OH and Val6-NH (7.75 ppm), 
and ThrS-OH and Leu7-NH (8.19 ppm). The arrow indicates the 
dpN(i,i+l) coupling between ThrS-flH and VaP-NH. 
ters of resonances characteristic of peptides (i.e. downfield 
amide, ~H, and upfield side-chain protons). In agreement with 
the results from amino acid analysis, nine resonances were 
observed which disappeared upon addition of D20, i.e. eight 
amide protons (8.69-7.42 ppm), and one proton of  Thr-OH 
(5.36 ppm). 
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Fig. 2. Region of the ROESY spectrum of curcacycline A (in DMSO-d6) 
showing inter-residue dNN(i,i+ 1) connectivities between amide protons 
(Ft, F2:8.7-7.4 ppm); the diagonal peaks are boxed. 
The amino acid sequence of curcacycline A was determined 
by two-dimensional ~H-NMR experiments [16,17]. Intra-resi- 
due J-couplings displayed in the spectrum obtained by Ho- 
monuclear Hartmann-Hahn spectroscopy (HOHAHA) [11] 
were used to assign ~H-chemical shifts to the specific protons 
of individual amino acid residues; in particular the assignment 
of amide and Cot protons is a prerequisite for sequence determi- 
nation. The HOHAHA spectrum showed complete spin-spin 
coupling patterns for two Gly, one Thr, and one Val; for the 
four Leu residues most of the J-coupling connectivities could be 
dotN 
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Fig. 3. Intensities of cross peaks due to sequential d~N , dNN and dpN 
connectivities in the ROESY spectrum of curcacycline A corrected for 
the offset dependency according to [19]. 
Glyl  ~ Leu2~ Leu3 
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curcacycline A 
Fig. 4. Structure of curcacycline A.
distinguised. ~H-Chemical shift assignments for the amino acid 
residues of curcacycline A in DMSO-d6 are listed in Table 1. 
The assignment of cross peaks in the ROESY (two-dimen- 
sional rotating frame Overhauser ffect spectroscopy) spectrum 
of curcacycline A in DMSO-d 6 allowed the sequential assign- 
ment of amino acid residues and was based on the fact that 
irrespective of the secondary structure of proteins (or peptides), 
at least one distance between amide-NH, ctH and flH protons 
on adjacent residues is less than 3 A, thus giving rise to connec- 
tivities through space (NOEs) [18]. For curcacycline A, 
d=N(i,i+l) in particular, and less frequently dNN(i,i+I) and 
daN(i,i+l) connectivities were observed between adjacent resi- 
dues. Inter-residue d=N(Li+I) connectivities were found be- 
tween one GlyLot proton and Leu2-NH, Leu2-otH and Leu 3- 
NH, Leu3-otH and Glya-NH, two Glyn-ot protons and ThrS-NH, 
ThrS-czH and Val6-NH, Val6-otH and LeuT-NH, LeuT-otH and 
LeuS-NH, and LeuS-otH and GIyLNH (Fig. 1). In addition, 
dNy(i,i+l) connectivities were found between GlyLNH and 
LeuZ-NH, GIy4-NH and ThrS-NH, and VaI6-NH and LeuT-NH 
(Fig. 2), and a cross peak as a result of dBy(i,i+l) coupling 
between ThrLflH (4.32 ppm) and Val6-NH (Fig. 1). The sequen- 
tial day, dNN and dan connectivities for curcacycline A are 
summarized in Fig. 3, and presented as intensities of the corre- 
sponding cross peaks (in the ROESY spectrum) corrected ac- 
cording to [19]. The proposed structure for curcacycline A, 
consistent with these results, is shown in Fig. 4. 
In addition to the sequential connectivities mentioned above, 
cross peaks in the ROESY spectrum were also found between 
ThrS-NH (7.42 ppm) and ThrS-flH (4.32 ppm), ThrS-OH (5.36 
ppm) and ThrLNH, ThrS-OH and Val6-NH (7.75 ppm), and 
ThrS-OH and LeuT-NH (8.19 ppm) (Fig. 1). 
The coupling constants J~qN=. of Leu 3 and Leu 8 (J = 4.4 and 
4.3 Hz, respectively) were found to be rather small in compar- 
ison with those of Leu 7 and Leu 2 (J = 8.5 and 8.8 Hz, respec- 
tively) or J = 8.0 Hz reported for protected linear tetrapeptides 
in DMSO-d6 [20]. This indicates the cis rather than the trans 
configuration between LeuLotH and Leu3-NH, and Leu8-otH 
and LeuS-NH. 
Since many plants are known to synthesize both L- and n- 
amino acids, our current research is focused on the determina- 
tion of the absolute configurations of constituting amino acid 
residues. Subsequently, computerized modelling studies will be 
performed to establish the tertiary structure of curcacycline A. 
Finally, together with other structurally elucidated cyclic pep- 
tides from the genus Jatropha (e.g. labaditin [3]), curcacycline 
A will be subjected to structure-activity relationship (SAR) 
studies to find possible leads for the development of (immuno- 
modulatory) drugs. 
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